Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.50 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.50 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.50 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.50 |
| ▸ | PHGDH | O43175 | 1/20 | 0.48 |
| ▸ | MAPK3 | P27361 | 4/20 | 0.47 |
| ▸ | DCAF1 | Q9Y4B6 | 1/20 | 0.46 |
| ▸ | ACP3 | P15309 | 1/20 | 0.45 |
| ▸ | CTSA | P10619 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4596498 | 1.00 | MAPK1 (0.51) | MAPK1MEN1KMT2AKCNQ3KCNQ2 | |
| SCHEMBL17685984 | 0.87 | MEN1 (0.44) | MAPK1MEN1KMT2AKCNQ3KCNQ2 | |
| SCHEMBL4598226 | 0.87 | ROCK2 (0.50) | MEN1KMT2APHGDHDCAF1ACP3 | |
| SCHEMBL14691111 | 0.87 | PHGDH (0.50) | MAPK1MEN1KMT2APHGDHDCAF1 | |
| SCHEMBL14393701 | 0.85 | MAPK1 (0.47) | MAPK1MEN1KMT2AKCNQ3KCNQ2 | |
| SCHEMBL29739235 | 0.85 | KCNQ3 (0.49) | MAPK1MEN1KMT2AKCNQ3KCNQ2 | |
| SCHEMBL29751805 | 0.85 | MAPK1 (0.47) | MAPK1MEN1KMT2AKCNQ3KCNQ2 | |
| SCHEMBL22077638 | 0.84 | DCAF1 (0.43) | MAPK1MEN1KMT2APHGDHDCAF1 | |
| SCHEMBL14691522 | 0.84 | PHGDH (0.43) | MAPK1MEN1KMT2APHGDHDCAF1 | |
| SCHEMBL18162818 | 0.84 | ALDH1A1 (0.51) | MAPK1MEN1KMT2AKCNQ3KCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102438990-B | Substituted 2-acetamido-5-aryl-1, 2, 4-triazolones and use thereof | BAYER SCHERING PHARMA AG | 2014-08-20 | — | — | CN | disclosed |
| US-8796324-B2 | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-05 | — | — | US | disclosed |
| CN-103864704-A | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof | BAYER SCHERING PHARMA AG | 2014-06-18 | — | — | CN | disclosed |
| US-20120238607-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-09-20 | — | — | US | disclosed |
| US-8202895-B2 | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-19 | — | — | US | disclosed |
| US-20100261771-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238607-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | AADAC, NAT1, TNNT2 | MAPK1 1329/4885MEN1 3285/4885KMT2A 2731/4885 |
| US-20100261771-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | AADAC, NAT1, TNNT2 | MAPK1 1329/4885MEN1 3285/4885KMT2A 2731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.